Advancements and Applications of Antibody Drug Conjugates in HER2-Negative Breast Cancer

CEConversations

Innehåll tillhandahållet av Creative Educational Concepts. Allt poddinnehåll inklusive avsnitt, grafik och podcastbeskrivningar laddas upp och tillhandahålls direkt av Creative Educational Concepts eller deras podcastplattformspartner. Om du tror att någon använder ditt upphovsrättsskyddade verk utan din tillåtelse kan du följa processen som beskrivs här https://sv.player.fm/legal.

1M ago 50:54

MP3•Episod hem

Patients with triple-negative and HR-positive/HER2-negative breast cancer have limited treatment options after the development of endocrine resistance. This dearth of options is particularly acute for Black women and other marginalized patients and results in treatment disparities. Antibody-drug conjugates (ADCs) are novel agents which may improve patient outcomes. However, clinicians cannot implement them into practice appropriately or may be hesitant to use them altogether.

In this Grand Rounds activity, a breast cancer expert will guide participants through a discussion of criteria to select patients to receive ADCs, adverse event (AE) management, and strategies to foster equitable care of patients with metastatic breast cancer (mBC).
Learn more: https://www.ceconcepts.com/activity/advancements-and-applications-of-antibody-drug-conjugates-in-her2-negative-breast-cancer/

30 episoder

#Science #Fitness #Podcasting Education #Medicine #Craig Martin, PharmD, MBA; Dave Feola, PharmD, PhD #Craig Martin #MBA; Dave Feola #Covid #Pandemic #Vaccines #Viruses #Herd Immunity #Infection #Coronavirus